Clinical Trial

Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-center, single-arm, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib as adjuvant therapy in hepatocellular carcinoma (HCC) participants who are at high risk of recurrence after curative resection.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-06.
Trial Details
NCT Number NCT06454578
Lead Sponsor Qilu Hospital of Shandong University
Conditions Carcinoma, Hepatocellular
Enrollment 30 participants
Start Date 2024-07-24
Primary Completion 2026-12 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2024-08-01